| Otolaryngology |
1 |
1 |
| Child |
0 |
0.53 |
| Healthcare and Medical Technology |
0 |
0.53 |
| Pain Management |
0 |
0.46 |
| Clinical Research |
0 |
0.45 |
| Eosinophilic Esophagitis |
0 |
0.99 |
| Steroids |
0 |
0.38 |
| Esophagitis |
0 |
0.3 |
| Patient Safety |
0 |
0.26 |
| Dermatitis |
0 |
0.24 |
| Adverse Effects |
0 |
0.23 |
| Proton Pump Inhibitor |
0 |
0.23 |
| Asthma |
0 |
0.18 |
| Biologic Therapy |
0 |
0.18 |
| Diet |
0 |
0.15 |
| Esophagus |
0 |
0.15 |
| North Carolina |
0 |
0.15 |
| Refractory |
0 |
0.15 |
| Remission |
0 |
0.15 |
| Atopic Dermatitis |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.09 |
| Abdomen |
0 |
0.07 |
| Anaplastic Lymphoma Kinase |
0 |
0.07 |
| Dysphagia |
0 |
0.07 |
| Eczema |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Immunoglobulin A (IgA) |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Interleukin |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |
| New York |
0 |
0.07 |
| Pain |
0 |
0.07 |
| Rhinosinusitis |
0 |
0.07 |